RU2014111472A - Способ ингибирования клеточной активации, вызываемой инсулиноподобным фактором роста 1 - Google Patents
Способ ингибирования клеточной активации, вызываемой инсулиноподобным фактором роста 1 Download PDFInfo
- Publication number
- RU2014111472A RU2014111472A RU2014111472/10A RU2014111472A RU2014111472A RU 2014111472 A RU2014111472 A RU 2014111472A RU 2014111472/10 A RU2014111472/10 A RU 2014111472/10A RU 2014111472 A RU2014111472 A RU 2014111472A RU 2014111472 A RU2014111472 A RU 2014111472A
- Authority
- RU
- Russia
- Prior art keywords
- individual
- antibody
- antibody according
- administering
- effective amount
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Моноклональное антитело, которое специфически связывает эпитоп, состоящий из аминокислот 71-80 белка IAP человека, и является антагонистом связывания IAP с SHPS-1.2. Антитело по п.1, связанное с детектируемой группой.3. Антитело по п.1, связанное с терапевтической группой.4. Антитело по п.1, отличающееся тем, что антитело не разрушает связывание IAP с белком β.5. Фармацевтическая композиция, содержащая антитело по п.1 в фармацевтически приемлемом носителе.6. Антитело по п.1, отличающееся тем, что антитело выбирают из группы, состоящей из (a) моноклонального антитела, продуцируемого гибридомой NPG-1, и (b) моноклонального антитела, которое конкурирует за связывание с тем же эпитопом, что и эпитоп, связываемый моноклональным антителом, продуцируемым гибридомой NPG-1.7. Антитело по п.6, связанное с детектируемой группой.8. Антитело по п.6, связанное с терапевтической группой.9. Фармацевтическая композиция, содержащая антитело по п.6 в фармацевтически приемлемом носителе.10. Способ ингибирования действий IGF-1 у индивидуума, нуждающегося в этом, включающий введение индивидууму антитела по п.1.11. Способ ингибирования действий IGF-1 у индивидуума, нуждающегося в этом, включающий введение индивидууму антитела по 6.12. Способ лечения ретинопатии у индивидуума, включающий введение индивидууму эффективного количества антитела по п.1 или 6.13. Способ лечения атеросклероза у индивидуума, включающий введение индивидууму эффективного количества антитела по п.1 или 6.14. Способ лечения нефропатии у индивидуума, включающий введение индивидууму эффективного количества антитела по п.1 или 6.15. Способ лечения ишемической болезни сердца у индивидуума, включающий вв�
Claims (16)
1. Моноклональное антитело, которое специфически связывает эпитоп, состоящий из аминокислот 71-80 белка IAP человека, и является антагонистом связывания IAP с SHPS-1.
2. Антитело по п.1, связанное с детектируемой группой.
3. Антитело по п.1, связанное с терапевтической группой.
4. Антитело по п.1, отличающееся тем, что антитело не разрушает связывание IAP с белком β3.
5. Фармацевтическая композиция, содержащая антитело по п.1 в фармацевтически приемлемом носителе.
6. Антитело по п.1, отличающееся тем, что антитело выбирают из группы, состоящей из (a) моноклонального антитела, продуцируемого гибридомой NPG-1, и (b) моноклонального антитела, которое конкурирует за связывание с тем же эпитопом, что и эпитоп, связываемый моноклональным антителом, продуцируемым гибридомой NPG-1.
7. Антитело по п.6, связанное с детектируемой группой.
8. Антитело по п.6, связанное с терапевтической группой.
9. Фармацевтическая композиция, содержащая антитело по п.6 в фармацевтически приемлемом носителе.
10. Способ ингибирования действий IGF-1 у индивидуума, нуждающегося в этом, включающий введение индивидууму антитела по п.1.
11. Способ ингибирования действий IGF-1 у индивидуума, нуждающегося в этом, включающий введение индивидууму антитела по 6.
12. Способ лечения ретинопатии у индивидуума, включающий введение индивидууму эффективного количества антитела по п.1 или 6.
13. Способ лечения атеросклероза у индивидуума, включающий введение индивидууму эффективного количества антитела по п.1 или 6.
14. Способ лечения нефропатии у индивидуума, включающий введение индивидууму эффективного количества антитела по п.1 или 6.
15. Способ лечения ишемической болезни сердца у индивидуума, включающий введение индивидууму эффективного количества антитела по п.1 или 6.
16. Способ лечения злокачественного новообразования у индивидуума, включающий введение индивидууму эффективного количества антитела по п.1 или 6.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/219,276 US8613922B2 (en) | 2003-04-24 | 2011-08-26 | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) |
| US13/219,276 | 2011-08-26 | ||
| PCT/US2012/052384 WO2013032948A1 (en) | 2011-08-26 | 2012-08-24 | Method for inhibiting cellular activation by insulin-like growth factor-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014111472A true RU2014111472A (ru) | 2015-11-27 |
Family
ID=47756771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014111472/10A RU2014111472A (ru) | 2011-08-26 | 2012-08-24 | Способ ингибирования клеточной активации, вызываемой инсулиноподобным фактором роста 1 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US8613922B2 (ru) |
| EP (1) | EP2747784A4 (ru) |
| JP (1) | JP6277127B2 (ru) |
| KR (1) | KR20140090975A (ru) |
| CN (1) | CN104053452B (ru) |
| AU (1) | AU2012300314A1 (ru) |
| BR (1) | BR112014004385A2 (ru) |
| CA (1) | CA2846248A1 (ru) |
| CL (1) | CL2014000449A1 (ru) |
| HK (1) | HK1199212A1 (ru) |
| IL (1) | IL231162A0 (ru) |
| MX (1) | MX2014002296A (ru) |
| RU (1) | RU2014111472A (ru) |
| WO (1) | WO2013032948A1 (ru) |
| ZA (1) | ZA201401450B (ru) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8613922B2 (en) * | 2003-04-24 | 2013-12-24 | The University Of North Carolina At Chapel Hill | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) |
| HUE13746964T2 (hu) | 2012-02-06 | 2020-01-28 | Inhibrx Inc | CD47 antitestek és alkalmazási eljárásaik |
| CA2905418C (en) * | 2013-03-13 | 2023-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
| EP3046627B1 (en) * | 2013-09-18 | 2019-10-23 | The Board of Trustees of the Leland Stanford Junior University | Modulation of efferocytosis pathways for treatment of atherosclerotic disease |
| EP3808367A3 (en) * | 2014-09-15 | 2021-07-21 | The Board of Trustees of the Leland Stanford Junior University | Targeting aneurysm disease by modulating phagocytosis pathways |
| EP3261671B1 (en) * | 2015-02-27 | 2020-10-21 | The Board of Trustees of the Leland Stanford Junior University | Combination therapy for treatment of atherosclerosis |
| AU2016304794B2 (en) | 2015-08-07 | 2021-07-15 | ALX Oncology Inc. | Constructs having a SIRP-alpha domain or variant thereof |
| EP3397271B1 (en) * | 2015-12-30 | 2021-11-03 | Marshall University Research Corporation | Compositions and methods for treating retinopathy |
| KR102355240B1 (ko) * | 2016-04-14 | 2022-01-25 | 오제 이뮈노테라프틱스 | 신규한 항-SIRPa 항체 및 이들의 치료학적 적용 방법 |
| EP3443010A2 (en) * | 2016-04-14 | 2019-02-20 | Ose Immunotherapeutics | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| PL3658589T3 (pl) | 2017-07-26 | 2024-03-18 | Forty Seven, Inc. | Przeciwciała anty-sirp-alfa i powiązane sposoby |
| JP7395471B2 (ja) | 2017-10-13 | 2023-12-11 | オーセ イミュノセラピューティクス | 改変抗ＳＩＲＰａ抗体及びその使用 |
| BR112020009805A2 (pt) | 2017-12-01 | 2020-10-13 | Seattle Genetics, Inc. | antígeno do mesmo que liga especificamente cd47 humano, o anticorpo ou fragmento de ligação a antígeno, sequência de ácidos nucleicos, vetor de expressão, célula hospedeira, métodos para produzir o anticorpo ou fragmento de ligação a antígeno, para tratar um câncer que expressa cd47 num indivíduo e para induzir apoptose de uma célula que expressa cd47, e, anticorpo mascarado |
| AU2019233577A1 (en) | 2018-03-13 | 2020-09-03 | Ose Immunotherapeutics | Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies |
| BR112020018927A2 (pt) | 2018-03-21 | 2021-01-05 | ALX Oncology Inc. | Anticorpos contra proteína alfa reguladora de sinal e métodos de uso |
| MX2020013068A (es) * | 2018-07-10 | 2021-03-02 | Univ Kobe Nat Univ Corp | Anticuerpo anti proteína reguladora de señales alfa sirpalfana. |
| CN113302202B (zh) * | 2018-07-17 | 2024-01-30 | 赫利世弥斯株式会社 | 利用表达胰岛素样生长因子1异构体的脱氧核糖核酸构建体的神经病变的治疗 |
| MX2021014627A (es) | 2019-05-31 | 2022-01-06 | Alx Oncology Inc | Polipeptidos de citocinas enmascaradas. |
| BR112022004995A2 (pt) | 2019-09-18 | 2022-06-21 | Lamkap Bio Alpha AG | Anticorpos biespecíficos contra ceacam5 e cd3 |
| JP7436711B2 (ja) | 2021-06-04 | 2024-02-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗ｓｉｒｐ－アルファ抗体 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5432611A (en) | 1977-08-16 | 1979-03-10 | Nobuhiko Katsunuma | Glucocorticoid saving factor |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4859765A (en) | 1983-10-17 | 1989-08-22 | Syntex (U.S.A.) Inc. | Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture |
| US4863857A (en) | 1985-03-01 | 1989-09-05 | Board Of Regents, The University Of Texas System | Polypeptide complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known |
| NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4853871A (en) | 1987-04-06 | 1989-08-01 | Genex Corporation | Computer-based method for designing stablized proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| US6340674B1 (en) | 1993-03-26 | 2002-01-22 | Thomas Jefferson University | Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides |
| US5874231A (en) | 1994-08-22 | 1999-02-23 | Mcgill University | Methods of screening for non-hormone compounds which effect modulation of polypeptide translation |
| AU2232597A (en) | 1996-03-06 | 1997-09-22 | Chugai Seiyaku Kabushiki Kaisha | Method of screening apoptosis inducing substances |
| US6207673B1 (en) | 1997-03-12 | 2001-03-27 | The University Of North Carolina At Chapel Hill | Covalent conjugates of topoisomerase I and topoisomerase II inhibitors |
| US20030049841A1 (en) | 1997-06-16 | 2003-03-13 | Short Jay M. | High throughput or capillary-based screening for a bioactivity or biomolecule |
| AU740225B2 (en) | 1997-09-11 | 2001-11-01 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody inducing apoptosis |
| CA2226962A1 (en) | 1998-02-16 | 1999-08-16 | Marie Sarfati | Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection |
| US6753146B1 (en) | 1999-02-23 | 2004-06-22 | Eric F. Bernstein | System and method for evaluating agents which prevent oxidative damage |
| GB9930706D0 (en) | 1999-12-24 | 2000-02-16 | Medical Res Council | Composition for inhibiting macrophage activity |
| TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| US7282556B2 (en) | 2001-05-15 | 2007-10-16 | Emory University | Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47 |
| US7261892B2 (en) * | 2001-11-27 | 2007-08-28 | Celltech R&D Limited | Methods for diagnosis and treatment of epithelial-derived cancers |
| US20100215640A1 (en) | 2003-04-24 | 2010-08-26 | The University Of North Carolina At Chapel Hill | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| US8613922B2 (en) * | 2003-04-24 | 2013-12-24 | The University Of North Carolina At Chapel Hill | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) |
| US20040213792A1 (en) * | 2003-04-24 | 2004-10-28 | Clemmons David R. | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| CN101133083A (zh) | 2003-11-11 | 2008-02-27 | 中外制药株式会社 | 人源化的抗cd47抗体 |
| EP2629478B1 (en) | 2012-02-16 | 2018-05-16 | BlackBerry Limited | Method and apparatus for separation of connection data by perimeter type |
-
2011
- 2011-08-26 US US13/219,276 patent/US8613922B2/en not_active Expired - Fee Related
-
2012
- 2012-08-24 EP EP12827290.3A patent/EP2747784A4/en not_active Withdrawn
- 2012-08-24 CA CA2846248A patent/CA2846248A1/en not_active Abandoned
- 2012-08-24 MX MX2014002296A patent/MX2014002296A/es unknown
- 2012-08-24 WO PCT/US2012/052384 patent/WO2013032948A1/en active Application Filing
- 2012-08-24 RU RU2014111472/10A patent/RU2014111472A/ru not_active Application Discontinuation
- 2012-08-24 CN CN201280052718.4A patent/CN104053452B/zh not_active Expired - Fee Related
- 2012-08-24 KR KR1020147006742A patent/KR20140090975A/ko active Search and Examination
- 2012-08-24 JP JP2014527342A patent/JP6277127B2/ja not_active Expired - Fee Related
- 2012-08-24 BR BR112014004385-0A patent/BR112014004385A2/pt not_active IP Right Cessation
- 2012-08-24 AU AU2012300314A patent/AU2012300314A1/en not_active Abandoned
-
2013
- 2013-11-08 US US14/076,130 patent/US9475882B2/en not_active Expired - Fee Related
-
2014
- 2014-02-24 IL IL231162A patent/IL231162A0/en unknown
- 2014-02-25 CL CL2014000449A patent/CL2014000449A1/es unknown
- 2014-02-25 ZA ZA2014/01450A patent/ZA201401450B/en unknown
- 2014-12-22 HK HK14112792.9A patent/HK1199212A1/xx unknown
-
2016
- 2016-04-12 US US15/096,750 patent/US20160297866A1/en not_active Abandoned
- 2016-10-24 US US15/332,549 patent/US20170114134A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014002296A (es) | 2014-03-27 |
| NZ621515A (en) | 2016-03-31 |
| BR112014004385A2 (pt) | 2020-10-27 |
| CA2846248A1 (en) | 2013-03-07 |
| AU2012300314A1 (en) | 2014-03-13 |
| KR20140090975A (ko) | 2014-07-18 |
| EP2747784A4 (en) | 2015-05-06 |
| CN104053452B (zh) | 2016-11-09 |
| HK1199212A1 (en) | 2015-06-26 |
| US20120039896A1 (en) | 2012-02-16 |
| US8613922B2 (en) | 2013-12-24 |
| JP6277127B2 (ja) | 2018-02-07 |
| US9475882B2 (en) | 2016-10-25 |
| US20160297866A1 (en) | 2016-10-13 |
| EP2747784A1 (en) | 2014-07-02 |
| CL2014000449A1 (es) | 2015-01-16 |
| US20170114134A1 (en) | 2017-04-27 |
| US20140141002A1 (en) | 2014-05-22 |
| WO2013032948A1 (en) | 2013-03-07 |
| ZA201401450B (en) | 2014-11-26 |
| JP2014525940A (ja) | 2014-10-02 |
| IL231162A0 (en) | 2014-04-30 |
| CN104053452A (zh) | 2014-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014111472A (ru) | Способ ингибирования клеточной активации, вызываемой инсулиноподобным фактором роста 1 | |
| NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| PH12019500439A1 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| JP2014169326A5 (ru) | ||
| RU2013102225A (ru) | АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| EA201000018A1 (ru) | Лиофилизированные лекарственные формы иммуноглобулинов и способы их получения | |
| JP2014530226A5 (ru) | ||
| RU2571204C3 (ru) | Специфические связывающие агенты против в7-н1 | |
| JP2017507954A5 (ru) | ||
| JP2016502515A5 (ru) | ||
| UA113856C2 (xx) | Злитий білок для лікування порушень метаболізму | |
| JP2020536109A5 (ru) | ||
| AR086360A1 (es) | Polipeptidos anticuerpos que antagonizan cd40 | |
| EA201491773A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата | |
| JP2014502955A5 (ru) | ||
| WO2008050329A3 (en) | Novel sirnas and methods of use thereof | |
| EA201490004A1 (ru) | Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей | |
| EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела | |
| RU2014103288A (ru) | Слитые полипептиды релаксина и их применение | |
| RU2013143358A (ru) | Анти-fgfr4 антитела и способы их применения | |
| IN2014KN01714A (ru) | ||
| MX2010002053A (es) | Composiciones de proteinas de fusion de notch humanizadas y metodos de tratamiento. | |
| JP2015522252A5 (ru) | ||
| JP2010500370A5 (ru) | ||
| MX2023002554A (es) | Anticuerpos anti-il-1r3 humanizados. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170824 |